肿瘤电场治疗在伴有脑室腹腔分流管的胶质母细胞瘤患者中的安全性特征
回顾性分析2012年11月至2021年4月全球上市后监测数据中156例接受肿瘤电场治疗的伴脑室腹腔分流管胶质母细胞瘤患者,77%报告至少1例不良事件,最常见为阵列下非严重局限性皮肤不良事件(43%),6例发生7例次严重治疗相关不良事件,无分流管故障归因于肿瘤电场治疗。
要点
- 伴脑室腹腔分流管的胶质母细胞瘤患者中,肿瘤电场治疗相关不良事件以非严重局限性皮肤不良事件为主(43%)。
- 伴与不伴脑室腹腔分流管患者的不良事件发生率和类别相当。
- 6例伴分流管患者发生7例次严重治疗相关不良事件,无分流管故障归因于肿瘤电场治疗。
核心结论
- 真实世界环境中,肿瘤电场治疗在伴脑室腹腔分流管的胶质母细胞瘤患者中耐受性良好且安全性特征有利。
- 无证据表明肿瘤电场治疗干扰脑室腹腔分流管有效性。
- 结果提示肿瘤电场治疗或可安全用于伴脑室腹腔分流管患者。
研究设计与样本
- 回顾性分析2012年11月至2021年4月间接受肿瘤电场治疗(200 kHz)的伴脑室腹腔分流管(可调压/不可调压)胶质母细胞瘤患者的全球上市后主动监测数据。
- 共识别156例伴脑室腹腔分流管患者纳入分析。
- 不良事件采用监管活动医学词典24.0版评估。
主要发现
- 77%的患者报告至少1例不良事件。
- 最常见的肿瘤电场治疗相关不良事件为非严重、局限性的阵列下皮肤不良事件(43%)。
- 伴与不伴脑室腹腔分流管患者的不良事件发生率和类别相当。
- 6例伴分流管患者发生7例次严重肿瘤电场治疗相关不良事件:分流管部位皮肤糜烂(n=3)、分流管部位伤口裂开(n=2)和切除瘢痕伤口裂开(n=2)。
- 无分流管故障被判定与肿瘤电场治疗相关。
临床怎么用
- 原文结论认为肿瘤电场治疗在伴脑室腹腔分流管的胶质母细胞瘤患者中耐受性良好且安全性特征有利,结果提示或可安全用于该类患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Tumor Treating Fields (TTFields, 200 kHz) therapy is a noninvasive, locoregional cancer treatment approved for use in newly diagnosed glioblastoma (GBM), recurrent GBM, and malignant pleural mesothelioma. GBM patients with hydrocephalus may require implantation of a ventriculoperitoneal (VP) shunt, however, the current TTFields therapy label does not include the use of VP shunts in GBM patients due to insufficient safety data. This analysis evaluates the safety of TTFields therapy use in this population. METHODS: Unsolicited post-marketing global surveillance data from patients with GBM and a VP shunt (programmable/non-programmable) who received TTFields therapy between November 2012-April 2021 were retrospectively analyzed. Adverse events (AEs) were assessed using the Medical Dictionary for Regulatory Activities version 24.0. RESULTS: Overall, 156 patients with VP shunts were identified and included in this analysis. In total, 77% reported ≥ 1 AE; the most common TTFields therapy-related AEs were non-serious and localized, beneath-array skin AEs (43%). The incidence and categories of AEs were comparable between patients with or without VP shunts. Six patients with VP shunts experienced seven serious TTFields therapy-related AEs: skin erosion at the shunt site (n = 3); wound dehiscence at the shunt site (n = 2) and at the resection scar (n = 2). No shunt malfunctions were deemed related to TTFields therapy. CONCLUSIONS: In the real-world setting, TTFields therapy in GBM patients with VP shunts demonstrated good tolerability and a favorable safety profile. There was no evidence that TTFields therapy disrupted VP shunt effectiveness. These results suggest TTFields therapy may be safely used in patients with VP shunts.
引用
- Oberheim-Bush NA, Shi W, McDermott MW, et al. The safety profile of Tumor Treating Fields (TTFields) therapy in glioblastoma patients with ventriculoperitoneal shunts. J Neurooncol. 2022. PMID: 35639236. doi:10.1007/s11060-022-04033-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。